PeptideDB

4-(2-Bromoacetyl)benzonitrile 20099-89-2

4-(2-Bromoacetyl)benzonitrile 20099-89-2

CAS No.: 20099-89-2

4-(2-Bromoacetyl)benzonitrile (4-Cyanophenacyl bromide) can be used to synthesize STA-5312. STA-5312 is a potent and ora
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

4-(2-Bromoacetyl)benzonitrile (4-Cyanophenacyl bromide) can be used to synthesize STA-5312. STA-5312 is a potent and orally active microtubule inhibitor.

Physicochemical Properties


Molecular Formula C9H6BRNO
Molecular Weight 224.05
CAS # 20099-89-2
PubChem CID 98654
Appearance Off-white to yellow solid powder
Density 1.6±0.1 g/cm3
Boiling Point 342.4±22.0 °C at 760 mmHg
Melting Point 92-96 °C(lit.)
Flash Point 160.9±22.3 °C
Vapour Pressure 0.0±0.8 mmHg at 25°C
Index of Refraction 1.59
LogP 1.75
Hydrogen Bond Acceptor Count 2
Rotatable Bond Count 2
Heavy Atom Count 12
Complexity 210
Defined Atom Stereocenter Count 0
SMILES

BrC([H])([H])C(C1C([H])=C([H])C(C#N)=C([H])C=1[H])=O

Synonyms

4-Cyanophenacyl bromide
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


References

[1]. Development of a Practical Synthesis of STA-5312, a Novel Indolizine Oxalylamide Microtubule Inhibitor. Org. Process Res. Dev. 2007, 11, 2, 246–250.

[2]. Keizo Koya,et al. STA-5312, a novel tubulin inhibitor, demonstrates the anti-cancer activity against chemotherapy-resistant cancers. Cancer Res, Volume 45, 2004.


Solubility Data


Solubility (In Vitro) DMSO : ~100 mg/mL (~446.33 mM; with ultrasonication)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.5 mg/mL (11.16 mM)(saturation unknown) in 10% DMSO 40% PEG300 5% Tween-80 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 400 μL PEG300, mix well; then add 50 μL Tween-80 to the above system, mix well; then continue to add 450 μL of normal saline to make up to 1 mL. Preparation of normal saline: Dissolve 0.9 g of sodium chloride in ddH₂O and make up to 100 mL to obtain a clear and transparent normal saline solution.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 4.4633 mL 22.3164 mL 44.6329 mL
5 mM 0.8927 mL 4.4633 mL 8.9266 mL
10 mM 0.4463 mL 2.2316 mL 4.4633 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.